HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
JAZZ
Jazz Pharmaceuticals plc
JAZZ's fundamentals are strong, but it looks expensive: trading at 78x earnings, about four times its usual 20x. Its downside scenario is more than ten times its upside.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
JAZZ Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Under pressure |
JAZZ's revenue, profitability and cash flow are currently healthy, but its balance sheet is under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
JAZZ PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.1x | $240 | — |
| Cheap | 15x | $45.24 | -81% |
| Fair | 20x | $62.02 | -74% |
| Current | 78x | $240 | — |
| Expensive | 140x | $430 | +79% |
Historical ranges are pointers, not guarantees.
JAZZ's PE is in its expensive range at 78x. If earnings grow as analysts expect, today's price would be 9.1x next year's earnings, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
JAZZ Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
JAZZ has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
JAZZ Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $26.33 | +758% |
| Q3 2026 | $3.07 | +$9.28 |
| Q2 2026 | $14.63 | +$21.50 |
| Q1 2026 | $0.11 | -99% |
| Q4 2025 | -$5.84 | -168% |
| Q3 2025 | -$6.21 | -188% |
| Q2 2025 | -$6.87 | -218% |
| Q1 2025 | $7.36 | +52% |
| Q4 2024 | $8.65 | +42% |
JAZZ has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over JAZZ on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over JAZZ on profitability, with a higher operating margin.
JAZZ Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.2B | +10% |
| Q2 2026 | $1.2B | +16% |
| Q1 2026 | $1.1B | +19% |
| Q4 2025 | $1.2B | +10% |
| Q3 2025 | $1.1B | +6.7% |
| Q2 2025 | $1B | +2.1% |
| Q1 2025 | $897.8M | -0.5% |
| Q4 2024 | $1.1B | +7.5% |
JAZZ's revenue has grown year over year for six quarters in a row: $1.2B last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -33% | -38 points |
| Q2 2026 | 21% | +86 points |
| Q1 2026 | 31% | +38 points |
| Q4 2025 | 21% | +3.7 points |
| Q3 2025 | 5.1% | -20 points |
| Q2 2025 | -66% | -85 points |
| Q1 2025 | -6.2% | -14 points |
| Q4 2024 | 18% | +5.4 points |
JAZZ's operating margin was −33% last quarter, down 38 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over JAZZ on cash flow, with more consistent year-over-year improvement.
JAZZ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $489.9M | +6.6% |
| Q2 2026 | $397.6M | +424% |
| Q1 2026 | $388.5M | -6.6% |
| Q4 2025 | $345.8M | -10% |
| Q3 2025 | $459.4M | +18% |
| Q2 2025 | $75.9M | -77% |
| Q1 2025 | $415.9M | +60% |
| Q4 2024 | $385.3M | +145% |
JAZZ's free cash flow has been positive every quarter for seven years: $1.6B over the past year, up 21% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over JAZZ on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
JAZZ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -6.8% | -4.7M shares |
| 1 year | +5% | +3.1M shares |
| 3 years | -9.2% | -6.6M shares |
| 5 years | +5.6% | +3.4M shares |
| Available history | +12% | +7.2M shares |
JAZZ has 65M diluted shares, up 5% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $225M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $150M |
| Q4 2023 | $99.8M |
| Q3 2023 | $74.4M |
| Q4 2022 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
JAZZ Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.1x | Elevated |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 5.2x | High |
| Q4 2025 | 14.9x | High |
| Q3 2025 | 21.1x | High |
| Q2 2025 | 11.0x | High |
| Q1 2025 | 2.8x | Moderate |
| Q4 2024 | 2.7x | Moderate |
JAZZ's net debt is about 3.1 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
JAZZ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.6 | Neutral |
| Stochastic | 43.8 | Neutral |
JAZZ's weekly RSI is 58 (neutral) and its Stochastic is 44 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
JAZZ PE vs Healthcare Sector
| Metric | JAZZ | Sector median | Relative |
|---|---|---|---|
| PE | 78x | 26x | 203% above |
| PE % | 81 | 29 | 52 pts above |
JAZZ is trading at 78x earnings, a 203% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
JAZZ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $225.9 | 6.4% above |
| 20 week MA | $239.1 | 0.5% above |
| 50 week MA | $211.0 | 14% above |
| 100 week MA | $167.5 | 43% above |
| 200 week MA | $146.0 | 65% above |
JAZZ has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
JAZZ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $150.9 | $157.3 | +4.2% |
| 2021 | $157.3 | $128.2 | -18% |
| 2022 | $128.2 | $157.2 | +23% |
| 2023 | $157.2 | $123.0 | -22% |
| 2024 | $123.0 | $124.6 | +1.3% |
| 2025 | $124.6 | $170.5 | +37% |
| 2026 YTD | $170.5 | $240.4 | +41% |
JAZZ has the edge over HIMS on returns for 2026, with the stronger performance.